zurück

Eladocagene exuparvovec (aromatic L-amino acid decarboxylase (AADC) deficiency, patients aged ≥ 18 months)

Subject:

  • Active Sustance: Eladocagene exuparvovec
  • Name: Upstaza®
  • Therapeutic area: L-amino acid decarboxylase (AADC) deficiency
  • Pharmaceutical company: PTC Therapeutics International Limited

 

Time table:

  • Start: 15.08.2022
  • Final decision by G-BA: 02.02.2023
  • The decision remains valid until: 15.02.2028

 

Final decision:

  • Hint for a non-quantifiable additional benefit